HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
NTLA
Intellia Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.74B
Market Cap
$1.74B
Enterprise Val
$1.37B
P/E Ratio
-4.35
P/B Ratio
2.39
Trailing PEG (1Y)
0.24
As Of
Aug 19, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$727.7M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-57.79%
Return on Assets-47.29%
Current Ratio6.65
Debt/Equity0.10
LT Debt/Equity0.07
Revenue Per Share0.05

Income Statement

Jun 30, 2026
Revenue$7.7M
Cost of Revenue$0.00
Gross Profit$7.7M
R&D$82.6M
SG&A$37.8M
Operating Expenses$120.4M
Operating Income-$112.8M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$106.6M
EPS (Basic)$-0.80
EPS (Diluted)$-0.80
EBIT-$106.6M
EBITDA-$104.6M
Consolidated Income-$106.6M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$106.1M
Accounts Receivable$7.3M
Inventory$0.00
Current Assets$527.8M
LT Investments$228.3M
Property, Plant & Equipment$101.0M
Intangibles$0.00
Non-Current Assets$329.3M
Total Assets$857.2M
Accounts Payable$11.7M
Current Debt$23.3M
Current Liabilities$79.4M
LT Debt$50.1M
Non-Current Liabilities$50.1M
Total Liabilities$129.5M
Total Debt$73.4M
Retained Earnings-$2.79B
Shareholder Equity$727.7M
Shares Outstanding139,722,277

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$83.1M
Investing Cash Flow-$141.6M
Financing Cash Flow$196.1M
CapEx-$1.7M
Free Cash Flow-$84.8M
Depreciation & Amort.$2.1M
Stock-Based Comp$18.1M
Acquisitions / Disposals$0.00
Investment Activity-$139.9M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$194.6M
Dividends Paid$0.00
Net Change in Cash-$28.6M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h